FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Singer Jonathon M 		2. Issuer Name and Ticker or Trading Symbol

Sagent Pharmaceuticals, Inc. [ SGNT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP and CFO
(Last)          (First)          (Middle)

C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/29/2016
(Street)

SCHAUMBURG, IL 60195
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/29/2016     D    3665   (1) D $21.75   35063   D    
Common Stock   8/29/2016     U    7857   (2) D $21.75   27206   D    
Common Stock   8/29/2016     D    27206   (3) D $21.75   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option to Buy   $14.61   8/29/2016     D         34783      (4) 2/22/2026   Common Stock   34783   $7.14   0   D    
Stock Option to Buy   $20.16   8/29/2016     D         10638      (5) 2/18/2024   Common Stock   10638   $1.59   0   D    
Stock Option to Buy   $16.45   8/29/2016     D         12067      (6) 2/21/2023   Common Stock   12067   $5.30   0   D    
Stock Option to Buy   $20.10   8/29/2016     D         55000      (7) 9/19/2021   Common Stock   55000   $1.65   0   D    

Explanation of Responses:
( 1)  Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
( 2)  Pursuant to the Merger Agreement, these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for the Consideration.
( 3)  Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Consideration.
( 4)  Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
( 5)  Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
( 6)  Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
( 7)  Represents the disposition of options, which provided for vesting in four equal installments beginning September 19, 2012. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.65 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Singer Jonathon M
C/O SAGENT PHARMACEUTICALS, INC.
1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG, IL 60195

EVP and CFO

Signatures
/s/ Jonathon M. Singer 8/31/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Sagent (NASDAQ:SGNT)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Sagent Charts.
Sagent (NASDAQ:SGNT)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Sagent Charts.